Biosimilar Clinical Development: Scientific Considerations and New Methodologies - Couverture souple

Livre 77 sur 151: Chapman & Hall/CRC Biostatistics
 
9780367736521: Biosimilar Clinical Development: Scientific Considerations and New Methodologies

Synopsis

Biosimilars have the potential to change the way we think about, identify, and manage health problems. They are already impacting both clinical research and patient care, and this impact will only grow as our understanding and technologies improve. Written by a team of experienced specialists in clinical development, this book discusses various potential drug development strategies, the design and analysis of pharmacokinetics (PK) studies, and the design and analysis of efficacy studies.

Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.

À propos de l?auteur

Dr. Kerry B. Barker is the Vice-President and Head of Early Oncology Research Statistics at Pfizer, Dr. Sandeep Menon is the Vice-President and Head of Biostatistics Research and Consulting Center at Pfizer, Dr. Ralph D'Agostino is a professor of Mathematics and Statistics at Boston University, Dr. Siyan Xu is a senior principal biostatistician at Novartis and Dr.Bo Jin is the Director of Biostatistics in Early Oncology Research at Pfizer. All have been involved with biosimilars clinical development across all regions of the world.

Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.

Autres éditions populaires du même titre

9781482231694: Biosimilar Clinical Development: Scientific Considerations and New Methodologies

Edition présentée

ISBN 10 :  1482231697 ISBN 13 :  9781482231694
Editeur : Chapman & Hall/CRC, 2017
Couverture rigide